These Analysts Cut Their Forecasts On uniQure Following Q4 Results

Core Viewpoint - uniQure N.V. reported better-than-expected fourth-quarter results, with losses narrower than analyst estimates and sales exceeding expectations [1][2]. Financial Performance - The company reported quarterly losses of $0.56 per share, beating the analyst consensus estimate of losses of $0.94 per share [1]. - Quarterly sales amounted to $5.568 million, surpassing the analyst consensus estimate of $5.204 million [1]. Regulatory Update - The FDA advised against using Phase 1/2 study data as primary evidence for the marketing application of AMT-130, a gene therapy for Huntington's disease [2]. - The FDA recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study to proceed with the application [2]. Stock Market Reaction - Following the earnings announcement and regulatory news, uniQure shares dipped by 13.3%, trading at $9.12 [2]. Analyst Ratings - Mizuho analyst Uy Ear downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12 [3]. - Chardan Capital analyst Daniil Gataulin maintained a Buy rating but reduced the price target from $53 to $16 [3].